Date of Award

2026

Degree Name

Pharmaceutical Sciences

College

School of Pharmacy

Type of Degree

M.S.

Document Type

Thesis

First Advisor

Dr. A.R.M. Ruhul Amin

Second Advisor

Dr. Cynthia B. Jones

Third Advisor

Dr. Timothy Long

Abstract

Breast cancer is still one of the most common types of cancer and one of the most common causes of cancer-related deaths in women around the world. Despite significant advances in early detection and treatment strategies, drug resistance, systemic toxicity, and poor outcomes in aggressive subtypes continue to limit the overall effectiveness of cancer therapy. Natural compounds have become promising anticancer agents because they can target many different things and are not very toxic. Curcumin has shown promise as an anticancer drug, but it cannot be used in the clinic because it does not absorb well, breaks down quickly, and does not stay stable for long. To address these constraints, synthetic curcumin analogues like FLLL12 and TEL109 have been engineered to exhibit superior pharmacological characteristics, including increased potency and stability. The current study seeks to assess the anticancer properties of curcumin analogues FLLL12 and TEL109 in breast cancer cell lines using Sulforhodamine B (SRB) assay to determine cytotoxicity and IC50 values, and the Annexin V/7-AAD assay with flow cytometry to assess apoptosis in a dose- and time-dependent manner (24, 48 and 72 hours). The findings highlight the potential of these curcumin analogues as effective therapeutic agents for breast cancer through enhanced antiproliferative and pro-apoptotic effects with reduced toxicity.

Subject(s)

Drugs -- Research.

Breast -- Cancer.

Pharmaceutical chemistry.

Oncology.

Curcumin.

Synthetic drugs.

Cancer cells.

Cancer -- Treatment -- Research.

Breast -- Cancer -- Treatment -- Research.

Additional Files
Approval page 1.pdf (368 kB)
Approval page 2.pdf (260 kB)
Download

Share

COinS